Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comparative effectiveness casts first shadows across US industry

Nature Biotechnology volume 27, pages 211–212 (2009)Cite this article

Patient access is a key concern. “Nobody thinks it's a bad idea to distribute information to doctors and patients,” says Robert Moffit, a director at the Heritage Foundation in Washington, DC. “The issue is whether there will be restrictions on access to treatments and services,” he says. “It seems very clear to me that that's exactly what sponsors of the House bill want to do.”

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. New York

    Emily Waltz

Authors
  1. Emily Waltz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Waltz, E. Comparative effectiveness casts first shadows across US industry. Nat Biotechnol 27, 211–212 (2009). https://doi.org/10.1038/nbt0309-211

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0309-211

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing